Biosimilars are a good strategic fit for Amgen and it is leveraging its existing biologicals experience and capabilities to build upon an existing, successful biologicals development programme. However, it does not believe in forcing patients to use biosimilars. This is perhaps in contrast to the European Generic medicines Association (EGA), which believes that governments should introduce pricing and reimbursement policies to encourage the use of biosimilars [3].

Amgen believes that physicians and patients can be encouraged to use biosimilars by making the supporting data available in the product information, and that high quality data and the accountability of manufacturers will support the use of biosimilars. In this way the company believes that physicians and patients will gain trust in and thus ‘choose’ biosimilars.

Amgen gives the example of Japan Chemical Research Pharmaceuticals’ (JCR) biosimilar recombinant human erythropoietin kappa (JR-013), which was approved for renal anaemia in kidney dialysis patients and premature infants in Japan in 2010 (Epoetin alfa BS) [4]. By the first quarter of 2014 the biosimilar had achieved a market share of 74% compared to the reference product [Kyowa Hakko Kirin’s Espo (epoetin alfa)].

The reason, according to Amgen, that JCR has such a high market share ‘is that the physician and patient are choosing the biosimilar and they do that by choice, not by force’. This example, Amgen says is evidence ‘that the whole argument of naming is not as important to uptake as people say’ [5].

Amgen thinks that, in a similar way to JCR, they ‘can make the biosimilar programme more successful in Europe and globally’ [6].

Related articles
Biosimilars use in Europe varies widely

Guiding principles for biosimilars development

Use of biosimilars in Europe

References
1.   GaBI Online - Generics and Biosimilars Initiative. Amgen expands biosimilars programme [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Jan 23]. Available from: www.gabionline.net/Biosimilars/News/Amgen-expands-biosimilars-programmee 
2.   Derbyshire M. Amgen’s move into the biosimilars market. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(4):202-3 . doi:10.5639/gabij.2014.0304.048
3.   European Generic medicines Association (EGA). Frequently asked questions about biosimilar medicines [homepage on the Internet]. [cited 2015 Jan 23]. Available from: www.egagenerics.com/index.php/biosimilar-medicines/faq-on-biosimilars
4.   GaBI Online - Generics and Biosimilars Initiative. Biosimilar EPO and infliximab, adalimumab get formal Japanese approval [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Jan 23]. Available from: www.gabionline.net/Biosimilars/News/Biosimilar-EPO-and-infliximab-adalimumab-get-formal-Japanese-approval
5.   Alexander E. The biosimilar name debate: what’s at stake for public health. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(1):10-2. doi:10.5639/gabij.2014.0301.005
6.   Derbyshire M. Biosimilars collaboration at Amgen and Actavis.  Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(3):155-6. doi:10.5639/gabij.2014.0303.035

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro PharmaCommunications International. All Rights Reserved.